Please login to the form below

Not currently logged in
Email:
Password:

EADV congress

This page shows the latest EADV congress news and features for those working in and with pharma, biotech and healthcare.

Novartis' secukinumab has 'consistent' activity in psoriasis

Novartis' secukinumab has 'consistent' activity in psoriasis

The data - which was presented at the European Association of Dermatology and Venereology (EADV) Congress in Amsterdam this week - reinforces earlier studies suggesting that secukinumab was more effective in treating psoriasis ... Novartis reported

Latest news

  • Trial success for Novartis' psoriasis drug

    Trial success for Novartis' psoriasis drug. Novartis has presented data at the European Academy of Dermatology and Venereology Congress that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 ... Novartis has presented data

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics